The Native Antigen Company Releases Covid-19 Antigens

February 13, 2020

The Native Antigen Company has commercially introduced antigens that have been specifically derived from the Wuhan strain of novel coronavirus, now named Covid-19.

The Native Antigen Company has commercially introduced antigens that have been specifically derived from the Wuhan strain of novel coronavirus, now named Covid-19, it was announced in a Feb. 12, 2019 press release.

The recombinant proteins were derived using the company’s proprietary mammalian VirtuE expression system, which enables the introduction of proper protein folding and post-translational modifications to recombinant proteins. The newly derived antigens are now commercially available for use in infectious disease research, as well as assay and vaccine development.

“Our mission is to reduce the global burden of infectious disease by developing the highest-quality reagents in rapid response to emerging public health threats,” said Dr. Andy Lane, commercial director, The Native Antigen Company, in the press release. “As one of the first recognized suppliers to release 2019-nCoV [Covid-19] proteins, we are proud to be able to offer these antigens to in-vitro diagnostics and pharmaceutical researchers to help drive the development of serological assays and vaccines that will be vital in stemming the spread of this disease.”

Professor Richard Tedder, Department of Infectious Disease, Imperial College London, added, in the press release, “The Native Antigen Company’s Coronavirus antigens could aid the development of accurate serological assays to identify asymptomatic individuals who have been infected by the virus, and help to assess the true level of infection in any population. The availability of these antigens also supports researchers’ efforts to rapidly develop a vaccine against 2019-nCoV [Covid-2019] by providing vital reagents to measure vaccine responses.”

Source: The Native Antigen Company